… on single long-acting bronchodilator therapy or LABA/LAMA combination therapy, who still
have … counts ≥300 cells·µL −1 , could benefit from ICS/LABA/LAMA combination therapy. …

… shown that dual bronchodilation is a safe therapeutic approach and that it does not amplify
the possible AEs that are characteristic of LAMAs and LABAs when used as monotherapy. …

… to single long-acting bronchodilator therapy and dual bronchodilator therapy; the “Outcomes” …
fixed or free LABA/LAMA combination and single long-acting bronchodilator therapy were …

… of triple therapy. It is therefore necessary to clarify when the use of triple therapy is indicated
in COPD patients and when it is preferable to maintain treatment with dual bronchodilation. …

… evidence regarding fixed triple therapy as a therapeutic option and we summarize … therapy
from dual bronchodilation to triple therapy and step down from triple to double bronchodilation …

… Randomized trials report that single-inhaler triple therapy is more effective than dual
bronchodilators … single-inhaler triple therapy with dual bronchodilators in real-world clinical …

… = standard error; TRIBUTE = extrafine inhaled triple therapy versus dual bronchodilator
therapy in chronic obstructive pulmonary disease trial; TRINITY = single inhaler extrafine triple …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐acting
muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations have …

… Randomized trials of triple therapy including an inhaled … dual bronchodilators, likely resulting
from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator …

… combinations of bronchodilators of different … dual bronchodilator therapy, evidence for the
4 currently Food and Drug Administration-approved long-acting anticholinergic bronchodilators/…